EUVIMEDEUVIMED entdecken
Open Access

Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination

William M Patterson, Brady D Greene, Leben Tefera, James Bena, Alex Milinovich, Neil Mehta, Mina K Chung, Samir Kapadia, Lars G Svensson, Scott J Cameron

Journal of Thrombosis and Thrombolysis · 2023

DOI: 10.1007/s11239-022-02764-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2023. Verfasst von William M Patterson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 9500 Euclid Ave, J2-2, Cleveland, OH, 44195, USA. Hauptthemen laut MEDLINE: COVID-19, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NHLBI Division of Intramural Research, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccination against COVID-19 reduces infection-related mortality. Unfortunately, reports of vaccine-induced immune thrombotic thrombocytopenia (VITT) in individuals administered adenovirus-vector-based vaccines (ChAdOx1 nCoV-19 and Ad26.COV2.S) have spurred side effect concerns. To address vaccine hesitancy related to this, it is essential to determine the incidence of VITT (defined by a 50% decrease in platelet count and positive anti-PF4 immunoassay within 4-28 days after vaccination) among patients administered two doses of an mRNA-based COVID-19 vaccination. We identified a retrospective cohort of 223,345 patients in the Cleveland Clinic Enterprise administered a COVID-19 vaccine at any location in Northeast Ohio and Florida from 12/4/2020 to 6/6/2021. 97.3% of these patients received an mRNA-based vaccination. Patients with: (1) a serial complete blood count both before and after vaccination and (2) a decrease in platelet count of ≥ 50% were selected for chart review. The primary outcome was the incidence of thrombotic events, including venous thromboembolism (VTE) and arterial thrombosis, 4-28 days post vaccination. Of 74 cohort patients with acute thrombosis, 72 (97.3%) demonstrated clear etiologies, such as active malignancy. Of two patients with unprovoked thrombosis, only one had findings concerning for VITT, with a strongly positive anti-PF4 antibody assay. In this large, multi-state, retrospective cohort, of 223,345 patients (97.2% of whom received the mRNA-based mRNA-1273 or BNT162b2 vaccines), we detected a single case that was concerning for VITT in a patient who received an mRNA vaccine. The overwhelming majority of patients with a thrombotic event 4-28 days following vaccination demonstrated clear etiologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaHumansCOVID-19 VaccinesAd26COVS1BNT162 VaccineChAdOx1 nCoV-19Retrospective StudiesVaccination

Stichwörter der Autor:innen

COVID-19ThrombosisVaccine induced thrombotic thrombocytopeniamRNA vaccination

Substanzen

COVID-19 VaccinesAd26COVS1BNT162 VaccineChAdOx1 nCoV-19

Autor:innen und Institutionen

  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 9500 Euclid Ave, J2-2, Cleveland, OH, 44195, USA.
  • Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 9500 Euclid Ave, J2-2, Cleveland, OH, 44195, USA. cameros3@ccf.org.
  • Department of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. cameros3@ccf.org.
  • Department of Hematology, Tausig Cancer Center, Cleveland Clinic, Cleveland, OH, USA. cameros3@ccf.org.

Förderung

  • BLRD VA
  • NHLBI Division of Intramural Research
  • NHLBI NIH HHS

Zitieren

APA

Patterson, W. M., Greene, B. D., Tefera, L., Bena, J., Milinovich, A., Mehta, N., Chung, M. K., Kapadia, S., Svensson, L. G., & Cameron, S. J. (2023). Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-022-02764-9

Vancouver

Patterson WM, Greene BD, Tefera L, Bena J, Milinovich A, Mehta N, et al. Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination. Journal of Thrombosis and Thrombolysis. 2023. doi:10.1007/s11239-022-02764-9

BibTeX
@article{Patterson2023,
  author = {Patterson, William M and Greene, Brady D and Tefera, Leben and Bena, James and Milinovich, Alex and Mehta, Neil and Chung, Mina K and Kapadia, Samir and Svensson, Lars G and Cameron, Scott J},
  title = {Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2023},
  doi = {10.1007/s11239-022-02764-9}
}
Kostenlos starten →